Forigerimod (IPP-201101) – CD4 T-cell Modulator Peptide for Laboratory Research

描述

Forigerimod (CAS No. 497156-60-2), also known as IPP-201101, is a highly specialized bioactive peptide consisting of 21 amino acids derived from U1 small nuclear ribonucleoprotein 70 kDa. The peptide is phosphorylated at Ser140, which contributes to its potent biological activity as a CD4 T-cell modulator.

As a selective modulator of CD4 T-cell function, Forigerimod has demonstrated the ability to regulate immune responses, inhibit autophagy pathways, and modulate inflammatory signaling in preclinical models. This makes it a valuable tool in laboratory research focusing on autoimmune diseases, including systemic lupus erythematosus (SLE) and related immunopathologies.

Forigerimod’s ability to inhibit autophagy is particularly noteworthy, as autophagic processes are implicated in the pathogenesis of various autoimmune and inflammatory disorders. By modulating autophagy, Forigerimod allows researchers to explore novel therapeutic mechanisms for autoimmune regulation, T-cell signaling, and inflammatory pathway modulation.

Produced under GMP standards by a certified manufacturer, Forigerimod is supplied at high purity, ensuring consistent experimental outcomes. The peptide is provided as a lyophilized powder suitable for in vitro and in vivo laboratory studies. It supports both wholesale and retail orders for research institutions and laboratories.

Forigerimod is strictly for laboratory research use only and is not intended for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Forigerimod acts as a selective modulator of CD4 T-cell activity. By interacting with CD4 T-cell receptors, it regulates immune signaling and inhibits the autophagic process within these immune cells. The suppression of autophagy contributes to its ability to modulate inflammation and maintain immune homeostasis in experimental settings.

Key research applications include:

• Systemic Lupus Erythematosus (SLE) Studies – Evaluating T-cell regulation and immune modulation in preclinical lupus models.

• Autoimmune Disorder Research – Investigating mechanisms of immune tolerance and autoimmune pathophysiology.

• Autophagy Pathway Studies – Assessing the impact of autophagy inhibition on immune cell function and inflammatory signaling.

• T-cell Signaling Studies – Examining CD4 T-cell receptor interactions, activation pathways, and cytokine regulation.

• Inflammation and Immune Modulation Models – Studying the effects of peptide-mediated immune regulation in vitro and in vivo.

By modulating CD4 T-cell activity and autophagy, Forigerimod allows researchers to explore potential therapeutic mechanisms for autoimmune diseases, including the development of novel immunomodulatory interventions. Its targeted mechanism ensures precise experimental outcomes in controlled research environments.

Development & Research Background

Forigerimod was developed as a therapeutic research tool to investigate autoimmune diseases and T-cell modulation. The peptide’s design, derived from U1 small nuclear ribonucleoprotein 70 kDa and phosphorylated at Ser140, provides high specificity for CD4 T-cells while retaining potent biological activity.

Research using Forigerimod has contributed to understanding:

• The regulation of autophagy in autoimmune conditions.

• The role of CD4 T-cell modulation in systemic lupus erythematosus and related disorders.

• Novel mechanisms for controlling T-cell-mediated inflammatory responses.

• Preclinical evaluation of peptide-based immunomodulators.

Its high purity and reproducibility from GMP-certified production facilitate rigorous laboratory studies and preclinical experimental protocols.

Side Effects (For Reference in Research Models Only)

• Potential alterations in T-cell proliferation depending on dosage.

• Modulation of autophagy and inflammatory signaling in experimental models.

• Observed effects are dose- and context-dependent and should be monitored carefully during in vitro and in vivo studies.

Disclaimer

Forigerimod is supplied exclusively for laboratory research use. It is not intended for human or veterinary consumption, diagnostic, or therapeutic purposes.

Keywords

• CAS 497156-60-2

• IPP-201101 peptide

• CD4 T-cell modulator peptide

• Forigerimod autoimmune research

• GMP Forigerimod supplier

• Forigerimod SLE research

• Buy Forigerimod wholesale

• High purity research peptide

• Laboratory immunology peptide